FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955498242> ?p ?o ?g. }

• W2955498242 endingPage "1608" @default.
• W2955498242 startingPage "1597" @default.
• W2955498242 abstract "Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bone formation and decreasing serum markers of bone resorption, leading to increased BMD and reduction in fracture risk in humans. We aimed to evaluate the effects of romosozumab on bone tissue. In a subset of 107 postmenopausal women with osteoporosis in the multicenter, international, randomized, double-blind, placebo-controlled Fracture Study in Postmenopausal Women with Osteoporosis (FRAME), transiliac bone biopsies were performed either after 2 (n = 34) or 12 (n = 73) months of treatment with 210 mg once monthly of romosozumab or placebo to evaluate histomorphometry and microcomputed tomography-based microarchitectural endpoints. After 2 months, compared with either baseline values assessed after a quadruple fluorochrome labeling or placebo, significant increases (P < 0.05 to P < 0.001) in dynamic parameters of formation (median MS/BS: romosozumab 1.51% and 5.64%; placebo 1.60% and 2.31% at baseline and month 2, respectively) were associated with a significant decrease compared with placebo in parameters of resorption in cancellous (median ES/BS: placebo 3.4%, romosozumab 1.8%; P = 0.022) and endocortical (median ES/BS: placebo 6.3%, romosozumab 1.6%; P = 0.003) bone. At 12 months, cancellous bone formation was significantly lower (P < 0.05 to P < 0.001) in romosozumab versus placebo and the lower values for resorption endpoints seen at month 2 persisted (P < 0.001), signaling a decrease in bone turnover (P = 0.006). No significant change was observed in periosteal and endocortical bone. This resulted in an increase in bone mass and trabecular thickness with improved trabecular connectivity, without significant modification of cortical porosity at month 12. In conclusion, romosozumab produced an early and transient increase in bone formation, but a persistent decrease in bone resorption. Antiresorptive action eventually resulted in decreased bone turnover. This effect resulted in significant increases in bone mass and improved microarchitecture. © 2019 American Society for Bone and Mineral Research." @default.
• W2955498242 created "2019-07-12" @default.
• W2955498242 creator A5005574643 @default.
• W2955498242 creator A5006615047 @default.
• W2955498242 creator A5008203290 @default.
• W2955498242 creator A5008511705 @default.
• W2955498242 creator A5009972236 @default.
• W2955498242 creator A5013152392 @default.
• W2955498242 creator A5032907896 @default.
• W2955498242 creator A5060912313 @default.
• W2955498242 creator A5086578680 @default.
• W2955498242 creator A5088452203 @default.
• W2955498242 date "2019-06-24" @default.
• W2955498242 modified "2023-10-14" @default.
• W2955498242 title "Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment" @default.
• W2955498242 cites W171709646 @default.
• W2955498242 cites W175660244 @default.
• W2955498242 cites W1970864109 @default.
• W2955498242 cites W1977271471 @default.
• W2955498242 cites W1989783674 @default.
• W2955498242 cites W1996446495 @default.
• W2955498242 cites W2003754948 @default.
• W2955498242 cites W2014348419 @default.
• W2955498242 cites W2023781848 @default.
• W2955498242 cites W2032956576 @default.
• W2955498242 cites W2053266095 @default.
• W2955498242 cites W2064081312 @default.
• W2955498242 cites W2069860666 @default.
• W2955498242 cites W2087560312 @default.
• W2955498242 cites W2096425957 @default.
• W2955498242 cites W2096627331 @default.
• W2955498242 cites W2102024055 @default.
• W2955498242 cites W2120403731 @default.
• W2955498242 cites W2153703573 @default.
• W2955498242 cites W2164443365 @default.
• W2955498242 cites W2221806096 @default.
• W2955498242 cites W2311016995 @default.
• W2955498242 cites W2398309765 @default.
• W2955498242 cites W2520995084 @default.
• W2955498242 cites W2530133557 @default.
• W2955498242 cites W2531652035 @default.
• W2955498242 cites W2533066994 @default.
• W2955498242 cites W2547154847 @default.
• W2955498242 cites W2552211559 @default.
• W2955498242 cites W2563838328 @default.
• W2955498242 cites W2606320398 @default.
• W2955498242 cites W2754720807 @default.
• W2955498242 cites W2790723483 @default.
• W2955498242 doi "https://doi.org/10.1002/jbmr.3735" @default.
• W2955498242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7027577" @default.
• W2955498242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31233639" @default.
• W2955498242 hasPublicationYear "2019" @default.
• W2955498242 type Work @default.
• W2955498242 sameAs 2955498242 @default.
• W2955498242 citedByCount "84" @default.
• W2955498242 countsByYear W29554982422019 @default.
• W2955498242 countsByYear W29554982422020 @default.
• W2955498242 countsByYear W29554982422021 @default.
• W2955498242 countsByYear W29554982422022 @default.
• W2955498242 countsByYear W29554982422023 @default.
• W2955498242 crossrefType "journal-article" @default.
• W2955498242 hasAuthorship W2955498242A5005574643 @default.
• W2955498242 hasAuthorship W2955498242A5006615047 @default.
• W2955498242 hasAuthorship W2955498242A5008203290 @default.
• W2955498242 hasAuthorship W2955498242A5008511705 @default.
• W2955498242 hasAuthorship W2955498242A5009972236 @default.
• W2955498242 hasAuthorship W2955498242A5013152392 @default.
• W2955498242 hasAuthorship W2955498242A5032907896 @default.
• W2955498242 hasAuthorship W2955498242A5060912313 @default.
• W2955498242 hasAuthorship W2955498242A5086578680 @default.
• W2955498242 hasAuthorship W2955498242A5088452203 @default.
• W2955498242 hasBestOaLocation W29554982421 @default.
• W2955498242 hasConcept C104317684 @default.
• W2955498242 hasConcept C126322002 @default.
• W2955498242 hasConcept C126894567 @default.
• W2955498242 hasConcept C134018914 @default.
• W2955498242 hasConcept C137620995 @default.
• W2955498242 hasConcept C141071460 @default.
• W2955498242 hasConcept C142724271 @default.
• W2955498242 hasConcept C146562846 @default.
• W2955498242 hasConcept C170033053 @default.
• W2955498242 hasConcept C185592680 @default.
• W2955498242 hasConcept C204787440 @default.
• W2955498242 hasConcept C27081682 @default.
• W2955498242 hasConcept C2776350087 @default.
• W2955498242 hasConcept C2776541429 @default.
• W2955498242 hasConcept C2779277721 @default.
• W2955498242 hasConcept C2779329777 @default.
• W2955498242 hasConcept C55493867 @default.
• W2955498242 hasConcept C673006 @default.
• W2955498242 hasConcept C71924100 @default.
• W2955498242 hasConceptScore W2955498242C104317684 @default.
• W2955498242 hasConceptScore W2955498242C126322002 @default.
• W2955498242 hasConceptScore W2955498242C126894567 @default.
• W2955498242 hasConceptScore W2955498242C134018914 @default.
• W2955498242 hasConceptScore W2955498242C137620995 @default.
• W2955498242 hasConceptScore W2955498242C141071460 @default.
• W2955498242 hasConceptScore W2955498242C142724271 @default.

• next